Roche's Ocrevus receives EU approval for MS

The European Commission approved Ocrevus ocrelizumab from Roche (SIX:ROG; OTCQX:RHHBY) to treat the relapsing and primary progressive forms of multiple sclerosis (PPMS). Roche said Ocrevus is the first and only disease-modifying drug for PPMS approved in the EU.

In March 2017, FDA approved the second-generation humanized mAb against CD20 for the same indications (see BioCentury, March 30, 2017)...